Stockreport

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

Emergent BioSolutions Inc.  (EBS) 
Last emergent biosolutions inc. earnings: 4/30 04:08 pm Check Earnings Report
US:NYSE Investor Relations: investors.emergentbiosolutions.com
PDF GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract modification executing an o [Read more]